CD19-CAR-iNKT cells

CD19-CAR-iNKT cells are chimeric antigen receptor (CAR)-engineered invariant natural killer T (iNKT) cells designed to target CD19-expressing B-cell malignancies and autoimmune diseases. iNKT cells are a unique, rare subset of T cells that express a semi-invariant T-cell receptor (TCR) restricted to the monomorphic antigen-presenting molecule CD1d. Unlike conventional T cells, iNKT cells do not cause graft-versus-host disease (GvHD), making them highly suitable for off-the-shelf allogeneic cell therapies. CD19-CAR-iNKT cells combine the direct, CAR-mediated cytotoxicity against CD19+ cells with the natural immunoregulatory and tumor-homing properties of iNKT cells, which can also transactivate host NK cells and suppress alloreactive T-cell responses. Several academic institutions and biopharmaceutical companies, including Baylor College of Medicine, University Hospital Tübingen, Kuur Therapeutics, and Arovella Therapeutics, are developing CD19-CAR-iNKT cell candidates (such as KUR-502 and ALA-101) for B-cell lymphomas, leukemias, and autoimmune disorders.

Other names

CD19 CAR-NKT cellsCD-19 CAR-NKT cellsCD 19 CAR-NKT cellsCD19 CAR-iNKTCD-19 CAR-iNKTCD 19 CAR-iNKTCD19 CAR-iNKT cellsCD-19 CAR-iNKT cellsCD 19 CAR-iNKT cellsCD19-CAR-NKT cellsCD-19-CAR-NKT cellsCD 19-CAR-NKT cellsCD19-CAR-iNKTCD-19-CAR-iNKTCD 19-CAR-iNKTCD19-directed CAR-iNKT cellsCD-19-directed CAR-iNKT cellsCD 19-directed CAR-iNKT cellsCD19-targeted CAR-iNKT cellsCD-19-targeted CAR-iNKT cellsCD 19-targeted CAR-iNKT cells